White & Case LLP - News - White & Case Ramps Up Pharma-related Activity with Huvepharma Share Sale

Services	Sectors
Antitrust Asset Finance Banking Canada Capital Markets Climate Change Commercial Litigation Data Privacy Employment & Benefits Financial Restructuring and Insolvency India Indonesia Intellectual Property International Arbitration International Trade Israel Korea Latin America Mergers & Acquisitions Private Clients Pro Bono Project Finance Sovereign Wealth Funds Sovereigns Spain Taiwan Tax White Collar	Communications and Media Construction Environmental Funds Islamic Finance Mining and Metals Oil & Gas Pharmaceuticals and Healthcare Power Real Estate Sourcing & Technology Transactions

North America	Latin America	Europe		Asia	Middle East/Africa
Los Angeles Miami New York Silicon Valley Washington, DC	Mexico City Monterrey São Paulo	Almaty Ankara Berlin Bratislava Brussels Bucharest Budapest Düsseldorf Frankfurt Geneva Hamburg	Helsinki Istanbul London Milan Moscow Munich Paris Prague Stockholm Warsaw	Beijing Hong Kong Shanghai Singapore Tokyo	Abu Dhabi Doha Johannesburg Riyadh

White & Case Ramps Up Pharma-related Activity with Huvepharma Share Sale

London, October 19, 2010 ... Global law firm White & Case LLP has advised the shareholders in Huvepharma AD, a Bulgarian animal health company, on the agreed sale and primary issuance of shares to Citi Venture Capital International. The deal is the latest in a series of pharma-related deals done by corporate teams across the Firm.

Citi Venture Capital International, which is buying the shares, is a subsidiary of Citi Capital Advisers, the alternative asset management division of investment bank Citigroup. Upon completion of the transaction, Citi Venture Capital International will acquire a stake of approximately 38% in Huvepharma AD.

"That products can be distributed globally with a minimum of local adaptation is a major factor contributing to rapid worldwide growth in the pharma sector, a trend that is attracting private equity investors to innovative companies such as Huvepharma," said Andrew Weiler, the White & Case partner who led on the transaction.

Huvepharma AD is a fast-growing global pharmaceutical company which develops, manufactures, and markets human and animal health products. It has a significant distribution network which covers 70 countries across 6 continents, and has manufacturing facilities in both Europe and the USA. It develops and produces anticoccidials, veterinary products, including vitamins and mineral pre-mixes, feed additives, such as enzymes and sensoric additives, as well as APIs for both veterinary and human use.

White & Case's pharmaceuticals and healthcare group spans offices across the UK, Europe (including Brussels), the Americas, and Asia. Recent deals the team has worked on include: Representation of PPF Healthcare a.s. in connection with the acquisition of Euroclinicum a.s. which provides healthcare services in hospitals and policlinics, and operates pharmacy stores, from Alpha Union Invest, S.A.; acting for private equity firms Nordic Capital and Avista Capital Partners in their US$4.1 billion acquisition of the ConvaTec business unit from Bristol-Myers Squibb. ConvaTec is a world leader in the development and marketing of innovative wound therapeutics and ostomy care product; acting for WellPoint, Inc., the leading health benefits company in the US with approximately 28 million medical members, on its US$6.5 billion acquisition of WellChoice, Inc., the largest health insurer in the State of New York; and acting for Siemens AG in its €4.2 billion acquisition of Bayer's in-vitro medical devices business, acquired through a multinational transaction.

White & Case's team on the Huvepharma transaction was led by London Mergers and Acquisitions partner Andrew Weiler and assisted by partner David Eisenberg and associates Sevda Staykova and Jana Audrlicka.

About White & Case
White & Case LLP is a leading global law firm with lawyers in 36 offices in 25 countries. Among the first US-based law firms to establish a truly global presence, we provide counsel and representation in virtually every area of law that affects cross-border business. Our clients value both the breadth of our global network and depth of our US, English and local law capabilities in each of our regions and rely on us for their complex cross-border transactions, arbitration and litigation provided by our global practices.

Contact:
Charlotte McCubbin
Media Relations Executive
White & Case LLP
+ 44 20 532 2848

	Press Releases
Expertise Mergers & Acquisitions Corporate Lawyers Andrew C. Weiler David M. Eisenberg Sevdalena Staykova Jana Audrlicka Locations London	White & Case Ramps Up Pharma-related Activity with Huvepharma Share Sale London, October 19, 2010 ... Global law firm White & Case LLP has advised the shareholders in Huvepharma AD, a Bulgarian animal health company, on the agreed sale and primary issuance of shares to Citi Venture Capital International. The deal is the latest in a series of pharma-related deals done by corporate teams across the Firm. Citi Venture Capital International, which is buying the shares, is a subsidiary of Citi Capital Advisers, the alternative asset management division of investment bank Citigroup. Upon completion of the transaction, Citi Venture Capital International will acquire a stake of approximately 38% in Huvepharma AD. "That products can be distributed globally with a minimum of local adaptation is a major factor contributing to rapid worldwide growth in the pharma sector, a trend that is attracting private equity investors to innovative companies such as Huvepharma," said Andrew Weiler, the White & Case partner who led on the transaction. Huvepharma AD is a fast-growing global pharmaceutical company which develops, manufactures, and markets human and animal health products. It has a significant distribution network which covers 70 countries across 6 continents, and has manufacturing facilities in both Europe and the USA. It develops and produces anticoccidials, veterinary products, including vitamins and mineral pre-mixes, feed additives, such as enzymes and sensoric additives, as well as APIs for both veterinary and human use. White & Case's pharmaceuticals and healthcare group spans offices across the UK, Europe (including Brussels), the Americas, and Asia. Recent deals the team has worked on include: Representation of PPF Healthcare a.s. in connection with the acquisition of Euroclinicum a.s. which provides healthcare services in hospitals and policlinics, and operates pharmacy stores, from Alpha Union Invest, S.A.; acting for private equity firms Nordic Capital and Avista Capital Partners in their US$4.1 billion acquisition of the ConvaTec business unit from Bristol-Myers Squibb. ConvaTec is a world leader in the development and marketing of innovative wound therapeutics and ostomy care product; acting for WellPoint, Inc., the leading health benefits company in the US with approximately 28 million medical members, on its US$6.5 billion acquisition of WellChoice, Inc., the largest health insurer in the State of New York; and acting for Siemens AG in its €4.2 billion acquisition of Bayer's in-vitro medical devices business, acquired through a multinational transaction. White & Case's team on the Huvepharma transaction was led by London Mergers and Acquisitions partner Andrew Weiler and assisted by partner David Eisenberg and associates Sevda Staykova and Jana Audrlicka. About White & Case White & Case LLP is a leading global law firm with lawyers in 36 offices in 25 countries. Among the first US-based law firms to establish a truly global presence, we provide counsel and representation in virtually every area of law that affects cross-border business. Our clients value both the breadth of our global network and depth of our US, English and local law capabilities in each of our regions and rely on us for their complex cross-border transactions, arbitration and litigation provided by our global practices. Contact: Charlotte McCubbin Media Relations Executive White & Case LLP + 44 20 532 2848